Company intelligence / Profile preview
BioFactura
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
Overview
BioFactura has developed a pipeline of high-value biosimilars, biodefense medical countermeasures—including a lead smallpox therapeutic with significant BARDA funding—and first-in-class novel drugs. The company leverages its proprietary StableFast™ platform to enable rapid, cost-effective production of these products. Clinical progress includes advanced development contracts for its smallpox drug; other programs span from preclinical to clinical trial material manufacturing.[1][3][4][5]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Biosimilars (generic biologics)Monoclonal antibodies (mAbs)Novel biologics/therapeutic proteins (Note: The company focuses on biosimilars and novel drugs, including therapeutic proteins and antibodies[1][3][4].)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on BioFactura.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioFactura.